Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumors × olaparib × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 7 Breast Neoplasms 7 Fallopian Tube Neoplasms 6 Pancreatic Neoplasms 4 Neoplasms 4 Neoplasm Metastasis 4 Prostatic Neoplasms 3 Neuroendocrine Tumors 3 Lymphoma, Non-Hodgkin 3 Endometrial Neoplasms 3 Small Cell Lung Carcinoma 2 Pheochromocytoma 2 Paraganglioma 2 Osteosarcoma 2 Neuroblastoma 2 Multiple Myeloma 2 Metastatic Castration-resistant Prostate Cancer 2 Medulloblastoma 2 Glioma 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Uveal Melanoma 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Solid Tumors 1

Interventions

pembrolizumab 3 atezolizumab 2 Docetaxel 2 Cetuximab 2 zimberelimab 1 spartalizumab 1 ribociclib 1 pralsetinib 1 olaparib 1 ipatasertib 1 inavolisib 1 fludarabine phosphate 1 fludarabine 1 entrectinib 1 encorafenib 1 binimetinib 1 alectinib 1 adagrasib 1 Pemetrexed 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Injections 1 Fluorouracil 1 Cyclophosphamide 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04123366 2026-04-22

MK-7339-007

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡